| |
Phase II |
Phase III |
| Non-small cell lung cancer |
response rate, progression free survival |
overall survival, progression free survival |
| Small-cell lung cancer |
response rate, progression free survival |
overall survival, progression free survival |
| Mesothelioma |
response rate |
overall survival |
| Breast cancer |
response rate, progression free survival |
overall survival, progression free survival |
| Nasopharyngeal carcinoma |
response rate, time to progression |
overall survival, progression free survival |
| Thyroid cancer |
response rate |
progression free survival |
| Esophageal cancer |
response rate |
overall survival, progression free survival |
| Gastric cancer |
response rate |
overall survival |
| Colon rectal cancer |
response rate, progression free survival |
overall survival, progression free survival |
| Pancreatic cancer |
response rate, progression free survival, overall survival |
overall survival |
| Hepatocellular carcinoma |
response rate, progression free survival |
overall survival, time to progression |
| Biliary tract Cancer |
response rate, progression free survival |
overall survival |
| Cervical cancer |
response rate |
overall Survival, progression free survival |
| Endometrial Cancer |
response rate, progression free survival |
overall survival, recurrence free survival |
| Ovarian cancer |
response rate, progression free survival |
overall survival, progression free survival |
| Prostate Cancer |
time to PSA progression, progression free survival |
overall survival, progression free survival |
| Renal cell carcinoma |
response rate, progression free survival |
overall survival, progression free survival |
| Glioblastoma |
response rate, progression free survival |
overall survival, progression free survival |
| Melanoma |
response rate, Relapse free survival, disease
stabilization rate |
overall survival, progression free survival |